Health

Results: 2845-2856 of 8216

DRINKAWARE PARTNERS WITH ANDY’S MAN CLUB AND FOOTBALL LEGEND CHRIS KAMARA TO SAY TO MEN THAT ‘IT’S OKAY TO TALK ABOUT DRINKING’

PR Newswire associated0

Prof. Mike Chan's Precision Medicine Vision Validated by Landmark Human Cytology Study Mapping Over 400 Distinct Cell Types - with Special Focus on the Brain

VUNO's AI-Powered Cardiac Arrest Risk Management System Earns CE MDR and UKCA Certifications

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential

PR Newswire associated0

Alphyn Doses First Patients in CLEAR-AD1 Global Phase 2b Clinical Trial Program for Atopic Dermatitis

Campaign Against Living Miserably (CALM)

MENTAL HEALTH AWARENESS WEEK: 1 in 3 18-24-Year-Olds in the UK Regularly Experiencing Loneliness

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Business Wire logo

New Study from UK’s Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care

PR Newswire associated0

Mediso completes Cryo-Free MRI Magnet Tech Transfer from SSI

Monument Re Transfers €1.4bn Greycastle Portfolio to RGA and Strengthens European Life Insurance Consolidation Platform

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine